Long non‐coding RNA MALAT1 and its target microRNA‐125b associate with disease risk, severity, and major adverse cardiovascular event of coronary heart disease

Lv, Fanqin; Liu, Liang; Feng, Qiang

doi:10.1002/jcla.23593

Cited by 18 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have disclosed that several noncoding RNAs possess the potential as CHD biomarkers, such as lncRNA‐FA2H‐2, lncRNA metastasis‐associated lung adenocarcinoma transcript 1 and its potential target miR‐125b, and miR‐92a. 18 , 19 , 20 As described above, lnc‐GAS5 and miR‐21, as inflammatory regulators, play vital roles in diversified pathophysiological processes of the cardiovascular system. 3 , 9 , 14 The current study exhibited that lnc‐GAS5 was highly expressed, while miR‐21 was insufficiently expressed in CHD patients.…”

Section: Discussionmentioning

confidence: 99%

Relation of circulating lncRNA GAS5 and miR‐21 with biochemical indexes, stenosis severity, and inflammatory cytokines in coronary heart disease patients

Jiang

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Long noncoding RNA GAS5 (lnc‐GAS5) and its target microRNA‐21 (miR‐21) regulate blood lipid, macrophages, Th cells, vascular smooth muscle cells to participate in atherosclerosis, and related coronary heart disease (CHD). The study aimed to further explore the linkage of their circulating expressions with common biochemical indexes, stenosis severity and inflammatory cytokines in CHD patients. Methods Ninety‐eight CHD patients and 100 controls confirmed by coronary angiography were enrolled. Plasma samples were collected for lnc‐GAS5 and miR‐21 detection by reverse transcription‐quantitative polymerase chain reaction and inflammatory cytokines determination by enzyme‐linked immunosorbent assay. Results Lnc‐GAS5 was increased in CHD patients compared with controls (2.270 (interquartile range [IQR]: 1.676–3.389) vs. 0.999 ([IQR: 0.602–1.409], p < 0.001), whereas miR‐21 showed opposite tread (0.442 [IQR: 0.318–0.698] vs. 0.997 [IQR: 0.774–1.368], p < 0.001). In aspect of their intercorrelation, lnc‐GAS5 negatively linked with miR‐21 in CHD patients (p < 0.001) instead of controls (p = 0.211). Interestingly, among the common biochemical indexes, lnc‐GAS5 related to decreased high‐density lipoprotein cholesterol (p = 0.008) and increased C‐reactive protein (CRP) (p < 0.001), while miR‐21 correlated with lower total cholesterol (p = 0.024) and CRP (p < 0.001) in CHD patients. As stenosis degree, lnc‐GAS5 positively correlated with Gensini score (p < 0.001), but miR‐21 exhibited negative association (p = 0.003) in CHD patients. In terms of inflammatory cytokines, lnc‐GAS5 positively related to tumor necrosis factor α (TNF‐α) and interleukin (IL)‐17A, while miR‐21 negatively linked with TNF‐α, IL‐1β, IL‐6, and IL‐17 in CHD patients (all p < 0.05). Conclusion Circulating lnc‐GAS5 and its target miR‐21 exhibit potency to serve as biomarkers for CHD management.

show abstract

Section: Discussionmentioning

confidence: 99%

Relation of circulating lncRNA GAS5 and miR‐21 with biochemical indexes, stenosis severity, and inflammatory cytokines in coronary heart disease patients

Jiang

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Furthermore, the relative expression was calculated by the 2 −∆∆Ct method, and GAPDH was used as an internal reference. In addition, primer sequences were constructed according to a previous study 13 …”

Section: Methodsmentioning

confidence: 99%

A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events

Jin

Liu

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Long noncoding RNA MALAT1 (lnc‐MALAT1) modulates atherosclerotic progression, myocardial ischemia injury, and systematic inflammation, which may be closely involved in acute myocardial infarction (AMI) pathogenesis. Thus, the current study intended to explore the relationship of lnc‐MALAT1 to disease risk, features, cytokines, and prognostication in AMI patients. Methods This multicenter study consecutively enrolled 160 newly diagnosed AMI patients and 50 controls (angina pectoris patients). Their peripheral blood mononuclear cells were obtained to measure lnc‐MALAT1 by RT–qPCR. Serum cytokines in AMI patients were detected by ELISA. In addition, AMI patients were followed up for major adverse cardiovascular event (MACE) risk evaluation. Results Lnc‐MALAT1 was higher in AMI patients than in controls (median: 2.245 vs. 0.996, p = 0.004), and it also presented a good capacity for differentiating AMI patients from controls with an area under the curve of 0.823. Lnc‐MALAT1 was positively related to C‐reactive protein (p = 0.005), low‐density lipoprotein cholesterol (p = 0.022), cardiac troponin I (p = 0.021), and infarct size (p = 0.007), but not other biochemical indexes in AMI patients. Meanwhile, lnc‐MALAT1 was positively associated with tumor necrosis factor‐alpha (p = 0.001), interleukin (IL)‐6 (p = 0.031), IL‐17A (p = 0.042), vascular cell adhesion molecule‐1 (p = 0.004), and intercellular adhesion molecule‐1 (p = 0.021) among AMI patients. Importantly, after categorization, lnc‐MALAT1 high (vs. low) was related to an elevated MACE accumulation rate (p = 0.035); furthermore, a higher lnc‐MALAT1 quartile showed a trend to be linked with an increased MACE accumulation rate (p = 0.092). Conclusion Lnc‐MALAT1 may serve as a biomarker for AMI risk, infarct size, inflammation and prognosis, but further validation by large‐scale studies is needed.

show abstract

“…In pulpitis, chronic pulmonary disease, and atherosclerosis, MEG3 presents proinflammatory effect. (Liu et al, 2021a;Song et al, 2020;Yan et al, 2019) Whereas in ulcerative colitis, ankylosing spondylitis, and rheumatoid arthritis, MEG3 has an anti-inflammatory effect. (Li et al, 2019a;Li et al, 2020c;Wang et al, 2021b) reduced the expression of p-PI3K and p-Akt.…”

Section: Downloaded Frommentioning

confidence: 99%

The Common LncRNAs of Neuroinflammation-Related Diseases

et al. 2022

View full text Add to dashboard Cite

Spatio-temporal specific lncRNAs play important regulatory roles not only in the growth and development of the brain but also in the occurrence and development of neurological diseases. Generally, the occurrence of neurological diseases is accompanied by neuroinflammation. Elucidation of the regulatory mechanisms of lncRNAs on neuroinflammation is helpful for the clinical treatment of neurological diseases. This paper focuses on recent findings on the regulatory effect of lncRNAs on neuroinflammatory diseases and selects ten lncRNAs that have been intensively studied to analyze their mechanism of action.The clinical treatment status of lncRNAs as drug targets is also reviewed. Significance StatementGene therapies such as CRISPR/Cas9 technology, antisense RNA technology and RNAi technology are gradually applied in clinical treatment, and the development of technology is based on a large number of basic research investigations. This paper focuses on the mechanisms of lncRNAs regulation of neuroinflammation, elucidates the beneficial or harmful effects of lncRNAs in neurosystemic diseases, and provides theoretical bases for lncRNAs as drug targets.

show abstract

Long non‐coding RNA MALAT1 and its target microRNA‐125b associate with disease risk, severity, and major adverse cardiovascular event of coronary heart disease

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 18 publications

References 23 publications

Relation of circulating lncRNA GAS5 and miR‐21 with biochemical indexes, stenosis severity, and inflammatory cytokines in coronary heart disease patients

Relation of circulating lncRNA GAS5 and miR‐21 with biochemical indexes, stenosis severity, and inflammatory cytokines in coronary heart disease patients

A novel circulating biomarker lnc‐MALAT1 for acute myocardial infarction: Its relationship with disease risk, features, cytokines, and major adverse cardiovascular events

The Common LncRNAs of Neuroinflammation-Related Diseases

Contact Info

Product

Resources

About